ATE526056T1 - Igf-2 peptid zur verwendung in einer tolerogenen behandlung für typ i diabetes - Google Patents

Igf-2 peptid zur verwendung in einer tolerogenen behandlung für typ i diabetes

Info

Publication number
ATE526056T1
ATE526056T1 AT03790946T AT03790946T ATE526056T1 AT E526056 T1 ATE526056 T1 AT E526056T1 AT 03790946 T AT03790946 T AT 03790946T AT 03790946 T AT03790946 T AT 03790946T AT E526056 T1 ATE526056 T1 AT E526056T1
Authority
AT
Austria
Prior art keywords
diabetes
type
igf
peptide
tolerogenic treatment
Prior art date
Application number
AT03790946T
Other languages
English (en)
Inventor
Vincent Geenen
Original Assignee
Univ Liege
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Liege filed Critical Univ Liege
Application granted granted Critical
Publication of ATE526056T1 publication Critical patent/ATE526056T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT03790946T 2002-08-30 2003-08-28 Igf-2 peptid zur verwendung in einer tolerogenen behandlung für typ i diabetes ATE526056T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US40727302P 2002-08-30 2002-08-30
US43229502P 2002-12-09 2002-12-09
US43802903P 2003-01-02 2003-01-02
PCT/EP2003/009623 WO2004019965A2 (en) 2002-08-30 2003-08-28 Thymus-based tolerogenic approaches for type i diabetes.

Publications (1)

Publication Number Publication Date
ATE526056T1 true ATE526056T1 (de) 2011-10-15

Family

ID=31982346

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03790946T ATE526056T1 (de) 2002-08-30 2003-08-28 Igf-2 peptid zur verwendung in einer tolerogenen behandlung für typ i diabetes

Country Status (7)

Country Link
US (1) US20040138116A1 (de)
EP (1) EP1536826B1 (de)
JP (1) JP2006509033A (de)
AT (1) ATE526056T1 (de)
AU (1) AU2003266331B2 (de)
CA (1) CA2496692A1 (de)
WO (1) WO2004019965A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1814393A4 (de) * 2004-11-04 2010-02-03 Med College Georgia Res Inst Tolerogener impfstoff und verfahren
GB0426644D0 (en) * 2004-12-03 2005-01-05 Univ Aberdeen T-cell modulation
US20070015689A1 (en) * 2005-06-23 2007-01-18 Alza Corporation Complexation of metal ions with polypeptides
EP1971361B1 (de) * 2005-12-23 2014-06-04 James D. Kelly Verbesserte schilddrüsen-stimulierende hormon-rezeptor-polypeptid-agonist-glykoformen zur behandlung des metabolischen syndroms
BR112016023983B1 (pt) 2014-05-07 2022-10-18 Boehringer Ingelheim International Gmbh Contentor para um nebulizador, nebulizador para um fluido e método para conectar um contentor a um dispositivo indicador
AU2016363025B2 (en) 2015-12-03 2021-04-08 Juno Therapeutics, Inc. Modified chimeric receptors and related compositions and methods
CN108114271B (zh) * 2016-11-29 2021-07-02 中国科学院上海营养与健康研究所 含胰岛素样生长因子-2的药物组合物及其应用
EP3609522A4 (de) * 2017-04-10 2021-05-05 Yoram Palti Verfahren und verbindungen zur behandlung von diabetes
MX2022000752A (es) * 2019-07-19 2022-03-25 Univ Michigan Regents Composiciones y metodos para tratar trastornos autoinmunes.
EP4228675A1 (de) * 2020-10-13 2023-08-23 Betavive Ltd. Verfahren und verbindungen zur behandlung von diabetes und assoziierten stoffwechselerkrankungen
WO2023062545A1 (en) 2021-10-12 2023-04-20 Betavive Ltd. Peptides and fragments for treating diabetes and associated metabolic diseases

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU613876B2 (en) * 1986-10-01 1991-08-15 Merck & Co., Inc. Synthetic genes encoding proteins from plasmid containing eucaryotic secretory signal peptides and process for secreting encoded proteins
GB8920381D0 (en) * 1989-09-08 1989-10-25 Greater Glasgow Health Board Treatment of insulin-resistant diabetes
US5827513A (en) * 1990-06-29 1998-10-27 Schering Corporation Methods of treating insulin-dependent diabetes mellitus by administration of IL-10
NL9102009A (nl) * 1991-11-29 1993-06-16 Stichting Katholieke Univ Produktie van bioactieve peptiden met recombinante cellen.
US5804560A (en) * 1995-01-06 1998-09-08 Sibia Neurosciences, Inc. Peptide and peptide analog protease inhibitors
US6277375B1 (en) * 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
NZ506447A (en) * 1998-02-23 2002-11-26 Neurocrine Biosciences Inc Peptide analogues of insulin with alanine substitutions and pharmaceutical use
US6287588B1 (en) * 1999-04-29 2001-09-11 Macromed, Inc. Agent delivering system comprised of microparticle and biodegradable gel with an improved releasing profile and methods of use thereof
JP2003528149A (ja) * 2000-03-24 2003-09-24 ジェネンテック・インコーポレーテッド 軟骨性疾患の治療のためのインスリンの使用

Also Published As

Publication number Publication date
JP2006509033A (ja) 2006-03-16
WO2004019965A2 (en) 2004-03-11
US20040138116A1 (en) 2004-07-15
CA2496692A1 (en) 2004-03-11
AU2003266331B2 (en) 2008-08-07
EP1536826B1 (de) 2011-09-28
EP1536826A2 (de) 2005-06-08
WO2004019965A3 (en) 2004-04-22
AU2003266331A1 (en) 2004-03-19

Similar Documents

Publication Publication Date Title
DE60330161D1 (de) Rifalazil zur behandlung von infektionen mit clostridium difficile
ATE286053T1 (de) Naphthyridinone zur hemmung der durch protein- tyrosin-kinase und zellzyklus kinase hervorgerufenen zellvermehrung
ATE495739T1 (de) Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
WO2003089457A3 (en) Peptide inhibitors of protein kinase c ϝ for pain management
CY1112055T1 (el) Συνθεσεις και μεθοδοι για την διαγνωση και θεραπευτικη αγωγη ογκου πνευμονα
YU9404A (sh) Multimerna, usmerena kontrastna sredstva na bazi peptida
CY1108563T1 (el) Μεθοδοι και υλικα για τη θεραπεια της ανεπαρκειας (ελλειψης) τεστοστερονης στους ανδρες
DE602005012276D1 (de) Verwendung von probiotischen bakterien zur herstellung von topischen zusammensetzungen zum schutz der haut
ATE458057T1 (de) Varianten der faktor-vii- oder -viia-gla-domäne
DE60013098D1 (de) Zusammensetzung zur hautdesinfizierung
CY1112487T1 (el) Βραχειας-δρασης ηρεμιστικοι υπνωτικοι παραγοντες για αναισθησια και καταστολη
DE60023816D1 (de) Verwendung von Lycopin in Zusammensetzungen zur Behandlung von Hautalterungs-Erscheinungen
EP2166845A4 (de) Alpha-connexin-c-terminale (act) peptide für die behandlung der altersbedingten makulardegeneration
ATE526056T1 (de) Igf-2 peptid zur verwendung in einer tolerogenen behandlung für typ i diabetes
DE502006007963D1 (de) Verwendung von hydrophobinen zur schmutzabweisenden behandlung von harten oberflächen
DE502005009908D1 (de) Verwendung von fluoreszierenden perlylenverbindungen zur behandlung menschlicher haare
SI1546182T1 (sl) Sestavki in postopki za diagnozo in zdravljenje tumorja
HRP20080617T3 (en) Treatment and diagnosis of neoplasms using thymic stromal lymphopoietin
ATE457736T1 (de) Zusammensetzung aus einem pulmonalen surfactant und einem von tnf stammenden peptid
ATE427956T1 (de) Ckrox-peptide und ihre analoge zur behandlung von hautalterung
ATE361914T1 (de) Cathepsincysteinproteaseinhibitoren und deren verwendung zur behandlung von entzündungen und immunerkrankungen
DK2118136T3 (da) Konsensuspeptid
DE602004005821D1 (de) Enteralpräparat zur vorbeugung gegen bzw. behandlung von sepsis
ATE406171T1 (de) Aplidine zur behandlung von multiplem myelom
ATE469659T1 (de) Stibogluconate-natrium und il-2 zur krebsbehandlung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties